Drug Trial Radar · NCT06431971
Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Dec 2027
Study completion Jul 2028
Sponsor
- Lead sponsor
- InnoMedica Schweiz AGIndustry
- Sponsor type
- Industry
- First posted
- May 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is double-blinded placebo controlled followed by an open-label extension placebo-to-active switch to estimate the efficacy of Talineuren. The investigational Medicinal Product (IMP) is administrated 48 times intravenously as an add-on therapy to the standard of care Parkinson medication. Talineuren is a liposomal formulation containing GM1 (monosialotetrahexosylganglioside) as the pharmacological active substance. The results of this pilot study are essential for the sample size calculation of a subsequent larger phase II/III trial.
Conditions
- Parkinson Disease
Interventions
TalineurenDrug
Talineuren infusion weekly
PlaceboDrug
Placebo infusion weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Movement Disorder Society Unified Parkinson's Disease Rating Scale scoreTime frame: Baseline, week 25 (primary endpoint)
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Neurologisches Institut Konolfingen
Konolfingen, Switzerland
Kantonsspital Aarau (KSA), Neurologische Klinik
Aarau, Canton of Aargau, Switzerland
Hôpitaux Universitaires de Genève (HUG), Département des Neurosciences cliniques NEUCLI, Service de Neurologie
Geneva, Canton of Geneva, Switzerland
Health Ostschweiz/ Kantonsspital St. Gallen (KSSG), Klinik für Neurologie
Sankt Gallen, Canton of St. Gallen, Switzerland
Centre hospitalier universitaire Vaudois (CHUV), Clinical Neurosciences Department
Lausanne, Canton of Vaud, Switzerland
Bellevue Medical Group AG (BMG), Neurozentrum Seefeld
Zurich, Canton of Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.